Search Results

Genflow Biosciences Plc an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier were duly passed.

ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report and Financial Statements for the year ended 31 December 2023, and the Notice of Annual General Meeting within it, have been posted to shareholders, and are available on the Company’s website.

Trinity Biotech plc, a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the first quarter 2024 on Thursday, May 23, 2024 at 8:30 AM ET.

ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE’s existing DNA damage response assay for the detection of micronuclei in CTCs as a measure of DDR.

ANGLE plc announces unaudited preliminary results for the year ended 31 December 2023.

ICON plc, a world-leading healthcare intelligence and clinical research organization, announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 1:30pm ET.

Genflow Biosciences Plc is pleased to announce that it will hold its Annual General Meeting at 12pm on Thursday 27 June 2024 at 1 Heddon Street, London, W1B 4BT.

Genflow Biosciences Plc is pleased to announce receipt of 50% of its substantial non-diluting and non-reimbursable research grant.

Hemogenyx Pharmaceuticals plc, the clinical stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to provide an update on its ongoing activities and progress.